Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.53 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21821086 | 0.87 | FAAH (0.64) | FAAHMGLL | |
| SCHEMBL21821149 | 0.87 | FAAH (0.52) | FAAHMGLLKDM4E | |
| SCHEMBL21821066 | 0.85 | FAAH (0.51) | FAAHMGLL | |
| SCHEMBL31168808 | 0.85 | FAAH (0.51) | FAAHMGLL | |
| SCHEMBL31168802 | 0.79 | FAAH (0.54) | FAAHMGLLKDM4EALDH1A1 | |
| SCHEMBL21821165 | 0.79 | FAAH (0.54) | FAAHMGLLKDM4EALDH1A1 | |
| SCHEMBL21821097 | 0.79 | FAAH (0.52) | FAAHMGLL | |
| SCHEMBL21896253 | 0.78 | FAAH (0.49) | FAAHMGLLSIGMAR1 | |
| SCHEMBL31168849 | 0.78 | FAAH (0.49) | FAAHMGLLSIGMAR1 | |
| SCHEMBL20556736 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634404-B1 | PYRAZOLE MAGL INHIBITORS | H LUNDBECK AS (DK) | 2024-11-20 | — | — | EP | disclosed |
| US-11149037-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| US-11149037-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| US-20200087304-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-03-19 | — | — | US | disclosed |
| US-20200087304-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149037-B2 | Pyrazole MAGL inhibitors | MAGI3, MAG, PYM1 | FAAH 112/4885MGLL 4/4885SIGMAR1 430/4885 |
| US-20200087304-A1 | PYRAZOLE MAGL INHIBITORS | MAGI3, MAG, PYM1 | FAAH 112/4885MGLL 4/4885SIGMAR1 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.